A Phase 2, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Two Injections of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Samumed
- 16 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Aug 2020.
- 16 Jul 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Aug 2020.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.